Stock TELO TELOMIR PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Telomir Pharmaceuticals, Inc. Stock

Equities

TELO

US87975F1049

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
6.865 USD +0.96% Intraday chart for Telomir Pharmaceuticals, Inc. -14.03% 0.00%
Apr. 16 Telomir Pharmaceuticals, Inc. Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C CI
Apr. 12 Telomir Pharmaceuticals, Inc. Announces Resignation of Christos Nicholoudis, Esq. as the General Counsel and A Member of the Board of Directors CI

Financials (USD)

Sales 2022 - Sales 2023 - Capitalization 203M
Net income 2022 - Net income 2023 -13M EV / Sales 2022 * -
Net cash position 2022 * - Net cash position 2023 * - EV / Sales 2023 * -
P/E ratio 2022 *
-
P/E ratio 2023 *
-
Employees 5
Yield 2022 *
-
Yield 2023 *
-
Free-Float 57.52%
More Fundamentals * Assessed data

Chart Telomir Pharmaceuticals, Inc.

Dynamic Chart

Latest news about Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C CI
Telomir Pharmaceuticals, Inc. Announces Resignation of Christos Nicholoudis, Esq. as the General Counsel and A Member of the Board of Directors CI
Telomir Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines CI
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data for Its Lead Development Product At Singapore Conference CI
Telomir Pharmaceuticals, Inc.(NasdaqCM:TELO) added to NASDAQ Composite Index CI
Telomir Pharmaceuticals, Inc. has completed an IPO in the amount of $7 million. CI
More news

Press releases Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C. AQ
Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024 AQ
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines AQ
Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th AQ
Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science AQ
More press releases

Quotes and Performance

1 day+0.96%
1 week-14.03%
Current month+33.30%
1 month+23.47%
More quotes

Highs and lows

1 week
5.50
Extreme 5.5
8.32
1 month
5.00
Extreme 5
9.39
Current year
4.76
Extreme 4.76
20.72
1 year
4.76
Extreme 4.76
20.72
3 years
4.76
Extreme 4.76
20.72
5 years
4.76
Extreme 4.76
20.72
10 years
4.76
Extreme 4.76
20.72
More quotes

Managers and Directors - Telomir Pharmaceuticals, Inc.

Managers TitleAgeSince
Christopher Chapman CEO
 Chief Executive Officer 71 21-08-25
Nathen Fuentes DFI
 Director of Finance/CFO 41 23-09-20
Michelle Yanez AUD
 Comptroller/Controller/Auditor 52 22-04-30
Members of the board TitleAgeSince
Christopher Chapman CEO
 Chief Executive Officer 71 21-08-25
Craig Eagle BRD
 Director/Board Member 57 22-10-31
Talhia Tuck BRD
 Director/Board Member 46 22-10-31
More insiders

Company Profile

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. TELOMIR-1 serve as a metal enzyme inhibitor of essential metals such as zinc and copper. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The Company’s BioMAP platform provides an unbiased, target-agnostic, and data-driven approach to understanding the effect of mono- or combination therapies on human disease models and translational biomarkers.
Sector
Pharmaceuticals
More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

1st Jan change Capi.
TELOMIR PHARMACEUTICALS, INC. Stock Telomir Pharmaceuticals, Inc.
0.00% 203M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. TELO Stock